Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Benefits of SGLT2 inhibitors in arrhythmias
Jinghan Gao, Genlong Xue, Ge Zhan, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 20

Showing 20 citing articles:

Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation
Akash Fichadiya, Amity E. Quinn, Flora Au, et al.
EP Europace (2024) Vol. 26, Iss. 3
Open Access | Times Cited: 14
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 7
Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Joyce Yip, Grace Shu Hui Chiang, I Lee, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 364-364
Open Access
Sodium Glucose Cotransporter 2 Inhibitors Across the Spectrum of Cardiovascular Kidney Metabolic Syndrome
Kevin Bryan Lo, Karim Iskarous, Rajiv Sankaranarayanan
Cardiology Clinics (2025)
Closed Access
Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors
Theodora M. Stougiannou, Konstantinos Christodoulou, Theocharis Koufakis, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 4, pp. 145-145
Open Access | Times Cited: 4
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
Vikash Jaiswal, Song Peng Ang, Danisha Kumar, et al.
JACC Advances (2025) Vol. 4, Iss. 3, pp. 101615-101615
Open Access
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, et al.
Pharmacology & Therapeutics (2025) Vol. 270, pp. 108861-108861
Open Access
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Imma Forzano, Scott Wilson, Angela Lombardi, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 9, pp. 839-847
Closed Access | Times Cited: 10
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 11, pp. 465-465
Open Access | Times Cited: 9
Effect of dapagliflozin on left ventricular structure and function in patients with non-ischemic dilated cardiomyopathy: An observational study
Jun Yeong Hong, Lei Huang, Nake Jin, et al.
Medicine (2024) Vol. 103, Iss. 13, pp. e37579-e37579
Open Access | Times Cited: 3
Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms
Adnan Shaaban, Shane S. Scott, Ashley Greenlee, et al.
Journal of Molecular and Cellular Cardiology (2024) Vol. 194, pp. 118-132
Open Access | Times Cited: 3
Dapagliflozin for Atrial Fibrillation
Na Li, Mihail G. Chelu, Yochai Birnbaum
Cardiovascular Drugs and Therapy (2024) Vol. 38, Iss. 1, pp. 1-3
Open Access | Times Cited: 2
Should atrial fibrillation be considered a vascular disease? The need for a comprehensive vascular approach
Carlos Escobar-Cervantes, Antonio Pose Reino, Pablo Díez‐Villanueva, et al.
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 11, pp. 779-790
Closed Access | Times Cited: 4
Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity
Reza Golchin Vafa, Amirreza Sabahizadeh, Ramina Mofarrah
Current Problems in Cardiology (2023) Vol. 49, Iss. 3, pp. 102350-102350
Closed Access | Times Cited: 4
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: A double-blind, randomized, placebo-controlled trial
Batool Zarei, Benyamin Fazli, Mohammad Tayyebi, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study
Talip E Eroglu, Ruben Coronel, Patrick C. Souverein
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 4, pp. 289-295
Closed Access | Times Cited: 1
Dapagliflozin and atrial fibrillation: elevated dosing to achieve class I antiarrhythmic effects?
Torsten Christ, Edzard Schwedhelm, Thomas Eschenhagen
Basic Research in Cardiology (2024) Vol. 119, Iss. 3, pp. 505-507
Open Access | Times Cited: 1
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial
Batool Zarei, Benyamin Fazli, Mohammad Tayyebi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 12, pp. 9935-9946
Closed Access | Times Cited: 1
Diabetes mellitus und Vorhofflimmern: Erhöhtes kardiales Risiko, fokussierte Therapiekonzepte
Denise Guckel, Christian Sohns
Deutsches Ärzteblatt (2024)
Open Access
Special focus on the new anti-diabetic drugs
Stefan Agewall
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 4, pp. 265-266
Closed Access
Diabetes mellitus und Vorhofflimmern: Erhöhtes kardiales Risiko, fokussierte Therapiekonzepte
Denise Guckel, Christian Sohns
Deutsches Ärzteblatt (2024)
Open Access
Page 1

Scroll to top